UNSPSC 51361505: Meparfynol or methylpentynol

This classification denotes a sedative and hypnotic with the molecular formula C6H10O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B017BC5B1N, chemically known as 2-butanol, 2-ethynyl- but generally known as meparfynol, which bears US NIH Compound Identifier 6494. European Medicines Agency schedules Methylpentynol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08869MIG.

The term METHYLPENTYNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules meparfynol in its Anatomical Therapeutic Chemical (ATC) Classification. Meparfynol or methylpentynol bears US NLM identifiers UMLS ID C0066418 and NCI Concept Code C76098. SMILES: CCC(C)(C#C)O.

UNSPSC 51361505 Meparfynol or methylpentynol is a Commodity code that does not map to the state and local procurement opportunities recently posted under it. The three most recent solicitations—Seminole County's procurement of naloxone and drug deactivation systems, the Texas Health and Human Services Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceuticals RFP—address naloxone products, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products respectively. None of these align with meparfynol or methylpentynol, a sedative or hypnotic pharmaceutical agent. The mismatch suggests either a miscoding error in the state and local procurement database or that this specific active pharmaceutical ingredient sees minimal sourcing activity through state and local channels.

No recent opportunities tagged to this code represent actual demand for meparfynol or methylpentynol itself. Firms evaluating this Commodity code should confirm with issuing bodies whether procurement systems are correctly routing substance-specific solicitations or whether demand for this ingredient occurs under broader pharmaceutical family codes. The absence of targeted sourcing activity under this code does not indicate market failure—it reflects the narrowness of the ingredient itself and the likelihood that any state or local use of meparfynol would be embedded in finished pharmaceutical products procured under higher-level UNSPSC families rather than as a raw material or active ingredient.